CASI Stock - CASI Pharmaceuticals, Inc.
Unlock GoAI Insights for CASI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $28.54M | $33.88M | $43.11M | $30.17M | $15.14M |
| Gross Profit | $11.15M | $20.05M | $27.28M | $17.61M | $5.63M |
| Gross Margin | 39.1% | 59.2% | 63.3% | 58.4% | 37.2% |
| Operating Income | $-39,621,000 | $-25,080,000 | $-26,491,000 | $-41,516,000 | $-52,781,000 |
| Net Income | $-39,258,000 | $-26,938,000 | $-41,014,000 | $-36,654,000 | $-48,287,000 |
| Net Margin | -137.6% | -79.5% | -95.1% | -121.5% | -318.9% |
| EPS | $-2.56 | $-2.02 | $-3.01 | $-2.69 | $-4.37 |
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
Visit WebsiteEarnings History & Surprises
CASIEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.36 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.40 | $-0.67 | -67.5% | ✗ MISS |
Q3 2025 | Aug 29, 2025 | $-0.47 | $-0.86 | -83.0% | ✗ MISS |
Q2 2025 | May 16, 2025 | $-0.61 | $-0.69 | -13.1% | ✗ MISS |
Q1 2025 | Mar 31, 2025 | $-0.60 | $-0.79 | -31.7% | ✗ MISS |
Q4 2024 | Nov 15, 2024 | $-0.62 | $-0.55 | +11.3% | ✓ BEAT |
Q3 2024 | Aug 16, 2024 | $-0.63 | $-0.52 | +17.5% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.05 | $-0.71 | -1320.0% | ✗ MISS |
Q1 2024 | Mar 28, 2024 | $-0.24 | $-0.29 | -20.8% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.56 | $-0.35 | +37.5% | ✓ BEAT |
Q3 2023 | Aug 11, 2023 | $-0.50 | $-0.77 | -54.0% | ✗ MISS |
Q2 2023 | Apr 26, 2023 | $-0.64 | $-1.44 | -125.0% | ✗ MISS |
Q1 2023 | Mar 29, 2023 | $-0.37 | $-0.40 | -8.1% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.51 | $-0.38 | +25.5% | ✓ BEAT |
Q3 2022 | Aug 12, 2022 | $-0.65 | $-0.56 | +13.8% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-1.00 | $-0.60 | +40.0% | ✓ BEAT |
Q1 2022 | Mar 28, 2022 | $-0.60 | $-0.40 | +33.3% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | $-0.60 | $-0.70 | -16.7% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.90 | $-0.50 | +44.4% | ✓ BEAT |
Q2 2021 | May 13, 2021 | $-0.50 | $-1.10 | -120.0% | ✗ MISS |
Latest News
CASI Pharmaceuticals Secures $20M Convertible Note Investment To Fund Phase 1 Renal Transplant Study In China
📈 PositiveCASI Pharmaceuticals Highlights Results From CID-103 Immune Thrombocytopenia Study Study At Annual ASH Meeting
➖ NeutralCASI Pharmaceuticals Q3 EPS $(0.67) Misses $(0.51) Estimate, Sales $3.075M Down From $7.793M YoY
📉 NegativeCASI Pharmaceuticals Receives Nasdaq Delisting Notification
📉 NegativeCASI Pharmaceuticals To Present Phase 1 CID-103 Data In Immune Thrombocytopenia At ASH 2025
📈 PositiveCASI Pharmaceuticals Advances Anti-CD38 Antibody CID-103 To Next Dose Cohort In Phase 1 ITP Trial
📈 PositiveHC Wainwright & Co. Reiterates Buy on CASI Pharmaceuticals, Maintains $4 Price Target
📈 PositiveCASI Pharmaceuticals Q2 EPS $(0.86) Misses $(0.47) Estimate, Sales $4.175M Miss $6.300M Estimate
📉 NegativeFrequently Asked Questions about CASI
What is CASI's current stock price?
What is the analyst price target for CASI?
What sector is CASI Pharmaceuticals, Inc. in?
What is CASI's market cap?
Does CASI pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CASI for comparison